Overexpression of PTTG1 has been observed in multiple cancers—including pancreatic (38), prostate (39), LUAD (40), and hepatocellular carcinoma (41)—and is strongly associated with tumor progression and poor prognosis (42). This evidence concerns the gene PTTG1 and neoplasm.